Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      APOC1 exacerbates renal fibrosis through the activation of the NF-κB signaling pathway in IgAN

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: IgA nephropathy (IgAN) is the most common disease leading to end-stage renal disease, and tubular fibrosis represents an important risk factor for disease progression. However, research on early molecular diagnostic indicators of tubular fibrosis and the mechanisms underlying disease progression is still lacking.

          Methods: The GSE93798 dataset was downloaded from the GEO database. DEGs were screened and analyzed for GO and KEGG enrichment in IgAN. The least absolute shrinkage and selection operator (LASSO) and support vector machine recursive feature elimination (SVM-RFE) algorithms were applied to screen for hub secretory genes. The expression and diagnostic efficacy of hub genes were confirmed by the GSE35487 dataset. ELISA was applied to detect the expression of APOC1 in serum. The expression and localization of hub genes in IgAN were verified by the expression of IHC and IF in human kidney tissues, and the correlation of expression with clinical data was verified in the Nephroseq database. Finally, cellular experiments clarified the role of hub genes in the signaling pathway.

          Results: A total of 339 DEGs were identified in IgAN, of which 237 were upregulated and 102 downregulated. The KEGG signaling pathway is enriched in the ECM–receptor interaction and AGE-RAGE signaling pathway. APOC1, ALB, CCL8, CXCL2, SRPX2, and TGFBI identified six hub secretory genes using the LASSO and SVM-RFE algorithms. In vivo and in vitro experiments demonstrated that APOC1 expression was elevated in IgAN. The serum concentration of APOC1 was 1.232 ± 0.1812 μg/ml in IgAN patients, whereas it was 0.3956 ± 0.1233 μg/ml in healthy individuals. APOC1 exhibited high diagnostic efficacy for IgAN (AUC of 99.091%, specificity of 95.455%, and sensitivity of 99.141%) in the GSE93798 dataset. APOC1 expression negatively correlated with eGFR ( R 2 = 0.2285, p = 0.0385) and positively correlated with serum creatinine ( R 2 = 0.41, p = 0.000567) in IgAN. APOC1 exacerbated renal fibrosis, possibly in part by activating the NF-κB pathway in IgAN.

          Conclusion: APOC1 was identified as the core secretory gene of IgAN, which was closely associated with blood creatinine and eGFR and had significant efficacy in the diagnosis of IgAN. Mechanistic studies revealed that the knockdown of APOC1 could improve IgAN renal fibrosis by inhibiting the NF pathway, which may be a potential therapeutic target for improving renal fibrosis in IgAN.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: not found
          • Article: not found

          Epidemiology of IgA Nephropathy: A Global Perspective

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-κB/TNF-α pathway

            Objective Macrophage-mediated inflammation plays a significant role in the development and progression of diabetic nephropathy (DN). However, the underlying mechanisms remain unclear. Studies suggest that T cell immunoglobulin domain and mucin domain-3 (Tim-3) has complicated roles in regulating macrophage activation, but its roles in the progression of DN are still completely unknown. Methods We downregulated Tim-3 expression in kidney (intrarenal injection of Tim-3 shRNA expressing lentivirus or global Tim-3 knockout mice) and induced DN by streptozotocin (STZ). We analyzed the degree of renal injury, especially the podocyte injury induced by activated macrophages in vitro and in vivo. Then, we transferred different bone marrow derived macrophages (BMs) into STZ-induced Tim-3 knockdown mice to examine the effects of Tim-3 on macrophages in DN. Results First, we found that Tim-3 expression on renal macrophages was increased in patients with DN and in two diabetic mouse models, i.e. STZ-induced diabetic mice and db/db mice, and positively correlated with renal dysfunction of DN patients. Tim-3 deficiency ameliorated renal damage in STZ-induced diabetes with concurrent increase in protein levels of Nephrin and WT-1. Similar effects were observed in mice with Tim-3 knockdown diabetic mice. Second, adoptive transfer of Tim-3-expressing macrophages, but not Tim-3 knockout macrophages, accelerated diabetic renal injury in DN mice, suggesting a key role for Tim-3 on macrophages in the development of DN. Furthermore, we found NF-κB activation and TNF-α excretion were upregulated by Tim-3 in diabetic kidneys, and podocyte injury was associated with the Tim-3-mediated activation of the NF-κB/TNF-α signaling pathway in DN macrophages both in vivo and in vitro. Conclusions These results suggest that Tim-3 functions as a key regulator in renal inflammatory processes and serves as a potential therapeutic target for renal injury in DN.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study

              IgA nephropathy (IgAN) has a clinical course that varies from asymptomatic nonprogressive to aggressive disease. However, few studies have investigated mortality in IgAN, and most of those that have done so lacked matched controls, did not report absolute risks, and had limited generalizability. In this nationwide cohort study in Sweden, the authors compared 3622 patients with IgAN with 18,041 matched general population controls, finding a 53% relative increase in mortality and a modest increase in absolute death rate, with one extra death per 310 person-years. On average, patients with IgAN died 6 years earlier than people without the disease. Excess mortality appeared to be limited to individuals with IgAN that had progressed to ESRD. These findings may have relevance to patient communication and policy development. The clinical course of IgA nephropathy (IgAN) varies from asymptomatic nonprogressive to aggressive disease, with up to one in four patients manifesting ESRD within 20 years of diagnosis. Although some studies have suggested that mortality appears to be increased in IgAN, such studies lacked matched controls and did not report absolute risk. We conducted a population-based cohort study in Sweden, involving patients with biopsy-verified IgAN diagnosed in 1974–2011; main outcome measures were death and ESRD. Using data from three national registers, we linked 3622 patients with IgAN with 18,041 matched controls; we also conducted a sibling analysis using 2773 patients with IgAN with 6210 siblings and a spousal analysis that included 2234 pairs. During a median follow-up of 13.6 years, 577 (1.1%) patients with IgAN died (10.67 per 1000 person-years) compared with 2066 deaths (0.7%) in the reference population during a median follow-up of 14.1 years (7.45 per 1000 person-years). This corresponded to a 1.53-fold increased risk and an absolute excess mortality of 3.23 per 1000 person-years (equaling one extra death per 310 person-years) and a 6-year reduction in median life expectancy. Similar increases in risk were seen in comparisons with siblings and spouses. IgAN was associated with one extra case of ESRD per 54 person-years. Mortality preceding ESRD was not significantly increased compared with controls, spouses, or siblings. Overall mortality did not differ significantly between patients with IgAN-associated ESRD and patients with ESRD from other causes. Patients with IgAN have an increased mortality compared with matched controls, with one extra death per 310 person-years and a 6-year reduction in life expectancy.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                25 May 2023
                2023
                : 14
                : 1181435
                Affiliations
                [1] 1 Department of Nephrology , Qilu Hospital of Shandong University , Jinan, Shandong, China
                [2] 2 Department of Blood Purification , Qilu Hospital of Shandong University , Jinan, Shandong, China
                [3] 3 Laboratory of Basic Medical Sciences , Qilu Hospital of Shandong University , Jinan, Shandong, China
                [4] 4 Department of Nephrology , Shengli Oilfield Central Hospital , Dongying, Shandong, China
                Author notes

                Edited by: Edgar Jaimes, Memorial Sloan Kettering Cancer Center, United States

                Reviewed by: Fang-Fang He, Huazhong University of Science and Technology, China

                Xiaoyue Tan, Nankai University, China

                *Correspondence: Xiangdong Yang, yxd@ 123456email.sdu.edu.cn
                Article
                1181435
                10.3389/fphar.2023.1181435
                10248024
                37305534
                78e7f568-9ff5-4b69-ad5e-eac7c10ab88b
                Copyright © 2023 Yu, Ding, An, Yang, Zhang, Li, Wang, Bai and Yang.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 07 March 2023
                : 02 May 2023
                Funding
                Funded by: National Natural Science Foundation of China , doi 10.13039/501100001809;
                Award ID: No. 82070746
                The research was supported by the National Natural Science Foundation of China (No. 82070746) and funded by the ECCM Program of the Clinical Research Center of Shandong University (No. 2021SDUCRCB007).
                Categories
                Pharmacology
                Original Research
                Custom metadata
                Renal Pharmacology

                Pharmacology & Pharmaceutical medicine
                apoc1,igan,biomarker,nk-κb,machine learning algorithms
                Pharmacology & Pharmaceutical medicine
                apoc1, igan, biomarker, nk-κb, machine learning algorithms

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content133

                Cited by3

                Most referenced authors365